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Abstract
The development of a topical microbicide blocking the sexual transmission of HIV-1 is urgently needed to control the global
HIV/AIDS pandemic. The actinomycete-derived lectin actinohivin (AH) is highly specific to a cluster of high-mannose-type
glycans uniquely found on the viral envelope (Env). Here, we evaluated AH’s candidacy toward a microbicide in terms of in
vitro anti-HIV-1 activity, potential side effects, and recombinant producibility. Two validated assay systems based on human
peripheral blood mononuclear cell (hPBMC) infection with primary isolates and TZM-bl cell infection with Env-pseudotyped
viruses were employed to characterize AH’s anti-HIV-1 activity. In hPMBCs, AH exhibited nanomolar neutralizing activity
against primary viruses with diverse cellular tropisms, but did not cause mitogenicity or cytotoxicity that are often associated
with other anti-HIV lectins. In the TZM-bl-based assay, AH showed broad anti-HIV-1 activity against clinically-relevant,
mucosally transmitting strains of clades B and C. By contrast, clade A viruses showed strong resistance to AH. Correlation
analysis suggested that HIV-19s AH susceptibility is significantly linked to the N-glycans at the Env C2 and V4 regions. For
recombinant (r)AH expression, we evaluated a tobacco mosaic virus-based system in Nicotiana benthamiana plants as a
means to facilitate molecular engineering and cost-effective mass production. Biochemical analysis and an Env-mediated
syncytium formation assay demonstrated high-level expression of functional rAH within six days. Taken together, our study
revealed AH’s cross-clade anti-HIV-1 activity, apparent lack of side effects common to lectins, and robust producibility using
plant biotechnology. These findings justify further efforts to develop rAH toward a candidate HIV-1 microbicide.
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Introduction
For nearly 30 years, HIV has posed serious global health
concerns. Millions of new HIV infections are reported every year
worldwide, mainly in developing regions where the availability of
antiretroviral drug therapies is extremely limited. As a result,
AIDS is among the leading causes of death in these regions [1].
The majority of infections are established via heterosexual
transmission and condom use is currently the only available
means to directly block this route of infection. As such, the need is
urgent for woman-controlled, safe, effective, and inexpensive
topical microbicides, until prophylaxis through vaccination
becomes globally available [2,3].
Current candidate microbicides under development encompass
chemical and physical agents as well as biologicals, including
virion-inactivating agents, entry/fusion inhibitors, reverse tran-
scriptase inhibitors, and others (www.microbicide.org). At this
point, it is not known which type of anti-HIV agents will be most
effective as topical microbicides; blocking of HIV-1 mucosal
transmission may require combinations of multiple agents [4,5].
Therefore, to broaden the options for different combinations in
HIV-1 microbicide development, it is important to expand the
candidate portfolio in each category of possible microbicide
components.
The envelope (Env) gp120 is heavily glycosylated with N-linked
glycans (NLGs), which generally account for more than half of the
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11143protein’s molecular mass [6]. Of these, HMGs represent a major
class. Because the Env glycans play critical roles in broad aspects
of the viral life cycle ranging from Env folding in host cells to viral
transmission and immune escape [7], they constitute an attractive
target for entry/fusion inhibitor-based microbicide development.
Lectins have attracted considerable attention in the search
for Env glycan-targeting microbicide candidates. Indeed, various
naturally occurring lectins have been shown to possess anti-HIV
activities. Examples include algae-derived cyanovirin-N (CV-N)
and griffithsin (GRFT) as well as plant-derived concanavalin A
(Con A) and snowdrop lectin, among others (reviewed in: [7]).
More recently, a Jacalin-related lectin isolated from the banana
fruit was shown to potently inhibit HIV-1 entry into target cells
[8]. Although conceptually not a lectin, the human monoclonal
antibody (mAb) 2G12 specifically binds to gp120 HMGs and
thereby neutralizes a wide spectrum of HIV-1 strains; thus, it is
counted among the very few broadly neutralizing mAbs isolated to
date [9,10].
AH was isolated from the actinomycete strain Longispora albida
K97-0003
T based on the inhibitory activity in a syncytium
formation assay [11]. A recent crystallographic analysis revealed
that AH is a monomeric protein and possesses three carbohy-
drate-binding sites [12]. Unlike several other known monosac-
charide-specific anti-HIV lectins such as GRFT, Con A, and
Galanthus nivalis agglutinin [7], AH specifically recognizes a
cluster of multiple HMGs via a collaborative action among the
protein’s three sugar-binding sites [12,13]. Because clustering
HMGs is a unique feature of Env glycans and not usually found
on host human proteins [14], AH is hypothesized to be a
superior anti-HIV-1 lectin with exquisite specificity to the virus;
hence, it may be devoid of unfavorable biological impacts in
humans.
In spite of the detailed studies in AH’s carbohydrate-binding
specificity [12,13,15], limited investigation has been reported with
regard to the protein’s anti-HIV activity in a syncytium formation
assay and in a multinuclear-activation-of-galactosidase-indicator
(MAGI) assay [15]. Because there is currently no in vitro assay that
can accurately predict in vivo efficacy of a candidate anti-HIV-1
agent, it is important to evaluate the activity of a potential anti-
HIV compound in multiple in vitro assay systems, preferably, those
that can closely simulate the in vivo situation and analyze anti-HIV-
1 activity in a broad-spectrum of clinically relevant viruses from
different clades [16]. Another important factor for a protein-based
microbicide candidate is the development of an efficient, cost-
effective recombinant expression system that is compatible with
extensive preclinical and clinical studies, global distribution, and
molecular design for the construction of stronger and/or safer
derivatives.
Thus, the primary objectives of our study were to reveal AH’s
anti-HIV-1 potential in validated in vitro neutralization assay
systems and to develop a robust expression platform for rAH. To
this end, we employed a human peripheral blood mononuclear
cell (hPBMC)-based neutralization assay using primary HIV-1
isolates and a reporter gene expressing TZM-bl cell-based
neutralization assay using Env-pseudotyped viruses from diverse
clades, including clinically relevant C-C chemokine receptor 5-
tropic (R5) HIV-1 strains. For recombinant expression of AH, we
tested a rapid and robust tobacco mosaic virus (TMV)-based
expression system in Nicotiana benthamiana plants. Thus, we provide
data implicating the feasibilities of AH in terms of its efficacy and
production viability. In addition, we performed a preliminary
analysis of AH to screen for potential side effects commonly noted
with antiviral lectins, i.e., cytotoxicity and mitogenic activity in
hPBMCs.
Methods
The hPBMC-based primary HIV-1 neutralization assay
The hPBMCs used in the HIV neutralization assay and
proliferation analysis described below were purchased from the
local blood center (American Red Cross Blood Center, Oakland,
CA) as an otherwise-discarded by-product of unsolicited blood
donations. No information about identity of the donors was
available to the investigators.
The assay was conducted essentially as described in D’Souza
et al. [17] and Mascola et al. [18]. Accordingly, the infectious
viruses were produced in hPBMCs. The hPBMCs were prepared
from buffy coats using Lymphocyte Separation Medium (LSM;
Cappel, Aurora, OH). To reduce variation of data from different
cell preparations, the cell samples from four different donors were
pooled and frozen so that a series of experiments was performed
using the same hPBMC pool. An inoculum of 100 50% tissue
culture infectious dose (TCID50) of HIV-1 was mixed with test
samples and incubated for 1 h at 37uC. Next, 3610
5 of
phytohemagglutinin (PHA)-stimulated hPBMCs were added and
incubated for 72 h, and washed to remove residual virus/sample
inoculum. After an additional 24-h incubation, cells were lysed
and p24 was quantified using a Beckman Coulter (Fullerton, CA)
HIV-1 p24 Antigen Assay Research Component Kit. Neutraliza-
tion was defined as the percent reduction in the amount of p24
detected with the test samples as compared to control. Inhibitory
concentrations of 50% (IC50) were determined via nonlinear
regression analysis using the GraphPad Prism 5 (GraphPad
Software, La Jolla, CA). Samples were analyzed in quadruplicate.
In each assay, anti-clusters of differentiation antigen 4 (CD4) mAb
B4 was used as a positive control [19]. To minimize inter-assay
variations of neutralization activity, sample IC50s were normalized
using B4 IC50 values obtained in each assay.
Cytotoxicity and mitogenic activity in hPBMCs
For cytotoxicity analysis, the CytoTox-ONE
TM Homogeneous
Membrane Integrity Assay Kit (Promega, Madison, WI) was used
to estimate cell viability. hPBMCs were prepared as described
above. A test sample was mixed with 2.5610
5 hPBMCs and
incubated for 6 h at 37uC. Cell viability treated with test samples
was calculated by relative lactate dehydrogenase activity in culture
medium of that in lysed cell controls.
The proliferative activity of AH in hPBMCs was analyzed by
carboxyfluorescein succinimidyl ester (CFSE) staining as described
in Elrefaei et al. [20], using the Molecular Probes CellTrace Kit
(Invitrogen, Eugene, OR). One million hPBMCs were labeled with
2 mM CFSE and cultured in the presence of a test sample (12.5 mg/
ml AH, 1 mg/ml staphylococcal enterotoxin B [SEB, a positive
control T cell stimulant [21]],or mediaalone [negativecontrol])for
5 days at 37uCi naC O 2 incubator. Cells were stained with BD
Pharmingen anti-human CD4 phycoerythrin (PE), anti-human
CD8 peridinin chlorophyll protein with a cyanine dye (PerCP-
Cy5.5), and anti-human CD3 allophycocyanin (APC; BD Biosci-
ences, San Jose, CA), and analyzed by an LSR II cell analyzer
(BD Biosciences) and FlowJo software (TreeStar, Ashland, OR).
Samples were first gated on viable lymphocyte population, and
percentage of proliferating cells was determined by measuring the
extent of CFSE dilution. The analysis was independently
performed three times, using hPBMCs from three different donors.
The TZM-bl-based Env-pseudotyped HIV-1 neutralization
assay
The antiviral activity of AH was assessed based on a reduction
in luciferase reporter gene expression after infection of TZM-bl
Anti-HIV Lectin Actinohivin
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described elsewhere [22], except that diethylaminoethyl cellulose
dextran was excluded upon infection. Antiviral activity was
expressed as an IC50 value, which is the sample concentration
giving 50% of relative luminescence units (RLUs) compared with
those of virus control after subtraction of background RLUs. Env-
pseudotyped viruses were prepared by co-transfection of 293T/17
cells with various env-expressing plasmids and an env-deficient
HIV-1 backbone vector (pSG3DEnv) and were titrated in TZM-bl
cells as previously described [22] to determine TCID50. The
Genbank accession numbers of the viruses used in the assay are
shown in Table 1. The broadly neutralizing mAbs b12, 2G12, 2F5
and 4E10, as well as soluble CD4 were used as positive controls.
Two-hundred TCID50 of pseudoviruses were used for the
neutralization assay. Samples and the virus were mixed and
incubated for 1 h at 37uC, to which 10
4 cells/well of TZM-bl
cells were added and incubated for 72 h. Luciferase activity was
measured using the Britelite Plus Reagent (PerkinElmer, Waltham,
MA).
Correlation analysis
Env potential NLG sites were determined based on sequons
(Asn-X-Thr/Ser-Y, where X and Y are any aa except for Pro)
using in Env sequences of viruses tested in the TZM-bl-based
assay (provided in Genbank) and the online tool N-Glycosite at
Los Alamos HIV Database (http://www.hiv.lanl.gov/content/
sequence/GLYCOSITE/glycosite) [23]. The correlation between
the IC50s and the number of sequons at whole or the selected Env
region was analyzed using the non-parametric Spearman’s
correlation coefficient in the GraphPad Prism 5 software. To
allow this analysis using all the viruses tested in the TZM-bl-based
assay, any IC50 values greater than the highest concentration
tested were arbitrary approximated to the next two-fold dilution
step (i.e., 50 mg/ml for experimental IC50s .25 mg/ml).
rAH expression in N. benthamiana
A ‘‘deconstructed’’ TMV replicon system (magnICON; Icon
Genetics GmbH, Halle/Saale, Germany) was used [24,25] to
express rAH in N. benthamiana. The native ath gene (Genbank
accession no. AB032371) was sub-cloned into the gene expression
module pICH11599 using Nco I and Sac I restriction sites to form
pNM86. The three component plasmids (pNM86, pICH20111,
and pICH14011) were each transferred into the Agrobacterium
tumefaciens strain GV3101 by electroporation. Bacteria were
resuspended in an infiltration buffer (10 mM 2-(N-morpholi-
no)ethanesulphonic acid [MES], 10 mM MgSO4, pH 5.5). Equal
portions of the three bacteria were then mixed to give an optical
density at 600 nm (OD600) of 0.1. N. benthamiana plants were
grown at 27uC and 55–65% humidity for 4 weeks under an 18 h-
light/6 h-dark cycle. Forty-eight h before inoculation, plants were
moved to an incubator set at 22uC and 55–65% humidity with the
same lighting cycle. The bacteria suspension was infiltrated into
leaves by application of a vacuum for 2 min at 25 inches Hg using
a vacuum pump. After infiltration, plants were placed in the
incubator set at 22uC and kept in darkness for 16 h. Subsequently,
the incubator was set to a normal 18 h-light/6 h-dark cycle. At 4
to 6 days post infiltration (dpi), infected leaves were harvested and
examined for rAH expression as described below.
Detection of rAH
Expression of rAH was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and western
blotting. Leaf materials were extracted with 5 v/w of SDS
extraction buffer (50 mM Tris-HCl [pH 6.8], 2% SDS, 0.003%
bromophenol blue, 10% glycerol). After electrophoresis, gels were
stained with Coomassie Brilliant Blue, or the resolved proteins
were electro-transferred to a poly (vinylidene difluoride) mem-
brane. Blots were probed with rabbit anti-AH antiserum (1:5,000)
followed by horseradish peroxidase (HRP)-conjugated goat anti-
rabbit immunoglobulin (Ig)G (1:10,000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), which were then detected using a
chemiluminescence luminol reagent (Santa Cruz Biotechnology).
The amounts of rAH in extract were quantified by gp120-
captured enzyme-linked immunosorbent assay (gp120-ELISA).
ELISA plates were coated with 0.3 mg/ml of HIV-1 gp120 CM
Env protein (National Institute of Health AIDS Research and
Reference Reagent Program [NIH ARRRP], Washington, D.C.)
and blocked with blocking buffer (phosphate-buffered saline
[PBS], pH 7.2, 0.05% Tween-20, 5% [w/v] non-fat dry milk).
Serially diluted extract samples were applied onto the plates and
incubated for 1 hr at 37uC. The gp120-bound rAH was detected
by rabbit anti-AH antiserum (1:3,000) followed by HRP-
conjugated goat anti-rabbit IgG (1:10,000). A tetramethylbenzi-
dine substrate (BioFX Laboratories, Owings Mills, MD) was used
for detection; absorbance at 450 nm was measured with a plate
reader (Beckman Coulter). A standard curve was created for each
plate using standard AH (5–300 ng/ml; purified from original
actinomycete culture), with which the amounts of rAH in samples
were calculated using the SoftMax Pro software (Molecular
Devices, Sunnyvale, CA).
Table 1. Anti-HIV-1 activity of AH against Env-pseudotyped
viruses in TZM-bl cells.
Genbank
Accession
No. IC50 (mg/ml)*
Virus Subtype Tropism 2G12 AH
MN.3 B AY669737.1 X4 ND 0.04
SF162.LS B EU123924.1 R5 0.7 .25
W61D 7.12 B AY973156.1 R5/X4 ND 9.9
Bal.26 B DQ318211.1 R5 0.9 1.5
SS1196.1 B AY835442.1 R5 10.8 0.01
Bx08.16 B GQ855765.1 R5 5.4 2.3
BZ167.12 B GQ855764.1 R5/X4 ND 2.9
6535.3 B AY835438.1 R5 2 .25
QH0692.42 B AY835439.1 R5 2.8 13.8
TRO.11 B AY835445.1 R5 0.4 6.7
RHPA.7 B AY835447.1 R5 .50 15.1
TV1.21 C AF391231.1 R5 1.7 0.3
92BR025.9 C U15121.1 R5 1.2 1.8
MW965.26 C U08455.1 R5 .25 2.5
ZM214M.PL15 C DQ388516.1 R5 .50 21.2
ZM109F.PB4 C AY424138.2 R5 .50 .25
Q461.e2 A AF407156.1 R5 .50 .25
Q259.d2.17 A AF407152.1 R5 .50 .25
Q842.d12 A AF407160.1 R5 .50 .25
Q168.a2 A AF407148.1 R5 .50 .25
*IC50s exceeding the highest concentrations of samples tested in the assay are
expressed as .25 or .50 mg/ml. ND: not determined.
doi:10.1371/journal.pone.0011143.t001
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The assay was performed as previously described, using HeLa/
env/tat and HeLa/CD4/lacZ cell lines [26]. To prepare leaf
extract samples for analysis, leaf materials were homogenized in
5 v/w of extraction buffer 1 (PBS, pH 7.4, 20 mM ascorbic acid,
10 mM sodium metabisulfite) and centrifuged. Most (.99%) of
the total gp120-binding rAH was retained in the insoluble pellet
fraction. The pellet was re-extracted with extraction buffer 2
(50 mM glycine, pH 2.5, 20 mM ascorbic acid, 10 mM sodium
metabisulfite, 6 M guanidine HCl). The extract was clarified by
centrifugation and dialyzed against 50 mM glycine (pH 2.5). The
dialyzed sample was centrifuged to remove insoluble materials and
concentrated using a centrifugal concentrator (3.5 kDa molecular
weight cut-off). The amount of rAH in each fraction was
quantified by gp120-ELISA, as described above. Typically, in
the dialyzed sample we obtained ,25 mg of rAH from one g of leaf
material.
For a quantitative assay, serially diluted samples and 9610
3
cells/well of HeLa/env/tat and HeLa/CD4/LacZ cells were
mixed in GIBCO Dulbecco’s modified Eagle’s medium (DMEM;
Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum, 1%
penicillin/streptomycin and 100 mg/ml kanamycin on a 96-well
plate and incubated for 18 h at 37uCi naC O 2 incubator. Cells
were washed and lysed with 0.05% Triton X-100. To quantify
syncytia, a developing reagent (60 mM Na2HPO4,4 0 m M
NaH2PO4, 10 mM KCl, 1 mM MgSO4, 50 mM 2-mercaptoeth-
anol, 0.8 mg/mL ortho-Nitrophenyl-b-galactoside) was added and
incubated at room temperature for 2 to 4 h. After stopping the
reaction with 2 M Na2CO3, the OD450 was read.
For staining of syncytia, HeLa/env/tat and HeLa/CD4/LacZ
(10
5 cells each/well) with or without a test sample were incubated
on an 8-well microscope slide (Nalge Nunc International,
Rochester, NY) for 18 h at 37uC. Cells were washed with PBS,
and fixed with 4% paraformaldehyde. Syncytia were stained with
5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) stain-
ing solution (25 ml PBS, pH 7.4, 2 mg/ml MgCl2, 1.64 mg/ml
potassium ferricyanide, 2.12 mg/ml potassium ferrocyanide,
1 mg/ml X-gal) for 18 h at 37uC and observed under an optical
microscope.
Results
AH inhibits hPBMC infection by primary HIV-1 isolates
Given that clustering HMGs is a conserved feature of the HIV-1
Env, broad anti-HIV-1 activity has been suggested for the HMG-
specific lectin AH. To prove this concept in an assay system
simulating the physiological conditions, we performed a hPBMC-
based neutralization assay using primary HIV-1 isolates [17,18].
Viruses with diverse cellular tropisms were tested, i.e., an R5 B
clade (SF162), an R5 C clade (ZA/97/009), a chemokine (C-X-C
motif) receptor 4-tropic (X4) B clade (HT/92/599), and a dual-
tropic R5X4 B clade (BZ167). The p24 production in the cells was
quantified to monitor HIV-1 infectivity. As shown in Figure 1A,
AH neutralized all the viruses with IC50s within the nanomolar
range (1 mg/ml of AH corresponds to 80 nM). Among the four
primary isolates tested, the R5-type C clade virus showed the
highest susceptibility to AH (IC50=0.12 mg/ml or 9.6 nM and
IC90=12.10 mg/ml or 968 nM) whereas the X4 B clade virus
was relatively resistant (IC50=2.68 mg/ml or 224 nM and
IC90=29.67 mg/ml or 2,370 nM). These results are congruent
with the previous findings in a surrogate MAGI assay, where AH
exhibited antiviral activity at the nanomolar dose range
(IC50s=2–110 nM) against three laboratory-adapted T- and M-
tropic strains (IIIB, NL4-3, and JR-CFS) and one T-tropic primary
isolate (O18A) [15]. Meanwhile, AH did not show any cytotoxicity
in hPBMCs at the highest concentration tested (50 mg/ml or
4 mM), indicating that the reduction of p24 production in the assay
was not due to cytotoxicity (Fig. 1B). Taken together, these results
demonstrated that AH can inhibit the infection of hPBMCs by
primary HIV-1 strains irrespective of cellular tropism, which
directly suggests the possibility of the protein’s in vivo efficacy.
AH does not induce hPBMC proliferation at a dose
exerting strong anti-HIV-1 activity
Many lectins are known to exhibit various biological effects on
human cells via their specific carbohydrate binding. For example,
Con A and PHA are well-known mitogens in human T cells [27].
The banana-derived lectin entry inhibitor BanLec effectively
proliferated CD3
+, CD4
+ and CD8
+ populations in hPBMCs at
Figure 1. Neutralization of primary HIV-1 isolates in hPBMCs. (A) The hPBMC-based neutralization assay. The reduction of p24 gag protein
production in hPBMCs was measured as an endpoint. hPBMCs (pooled from four different donors) were infected with R5 B clade (SF162), R5 C clade
(ZA/97/009), X4 B clade (HT/92/599), or R5X4 B clade (BZ167) in the presence of various concentrations of AH. Samples were analyzed in
quadruplicate.Results are expressed as mean 6 SEM. See Materials and Methods for assay details. Dose-dependent neutralization was observed for all
viruses. (B) Cytotoxicity analysis. Potential toxicity of AH in hPBMCs was analyzed based on the LDH activity in the culture medium after incubation of
hPBMCs with various concentrations of AH. Analysis was performed in quadruplicate in two different pools of hPBMCs. Results are expressed as
mean 6 SEM. The lack of hPMBC cytotoxicity was demonstrated for up to 50 mg/ml of AH.
doi:10.1371/journal.pone.0011143.g001
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Furthermore, strong mitogenic activity and cytotoxicity in
hPBMCs was observed for CV-N, which has been one of the
most studied HMG-specific anti-HIV-1 lectins to date [29,30].
Because hPBMC mitogenicity may lead to the disastrous side
effect of enhanced HIV-1 infectivity in these cells [29], it is
imperative to demonstrate that the anti-HIV-1 effect of a
candidate microbicide is not accompanied by mitogenic activity
in these cells. Therefore, we tested the proliferation potential of
hPBMCs upon exposure to AH. As shown in Figure 2, AH at
1 mM (or 12.5 mg/ml) did not show any sign of proliferative
activity either in a whole CD3
+ T cell population or in CD4
+ or
CD8
+ cells after prolonged incubation (for 5 days) with AH (Fig. 2).
These results are in sharp contrast to the protein’s nanomolar anti-
HIV-1 activity in the hPBMC-based neutralization assay, where
the same dose exerted a prominent HIV-1 neutralization effect
against primary isolates (Fig. 1A). Coupled with the data showing
AH’s lack of cytotoxicity up to 4 mM (see Fig. 1B), it is suggested
that AH anti-HIV-1 activity is not associated with some of the
major common side effects noted with other antiviral lectins.
Broad-spectrum anti-HIV-1 activity of AH against R5-type
viruses
To extend our examination on the breadth of AH’s anti-HIV-1
activity, we performed a reporter gene expression TZM-bl-based
neutralization assay using Env-pseudotyped viruses [22]. We
included multiple R5 A, B and C clade viruses in the analysis
because: 1) R5 viruses are transmitted predominantly during the
course of HIV-1 transmission [31,32] and are therefore particu-
larly important from an HIV-1 microbicide standpoint; and 2)
these three clades represent more than 70% of the viruses
currently circulating in the world [33,34]. Table 1 shows IC50so f
AH against clade A, B, and C isolates of AH and the HMG-
specific broadly neutralizing mAb 2G12. AH showed broad anti-
HIV-1 activity that was similar overall to that of 2G12, aside from
a few exceptions. Among the viruses tested, ZM109F.PB4 (R5 C
clade) and all the four A clade viruses showed IC50s of over 25 mg/
ml for both AH and 2G12. These results may indicate that clade A
viruses are generally highly resistant to the two HMG-specific anti-
HIV proteins compared to other subtypes. By contrast, the notable
difference between AH and 2G12 was seen with other viruses.
SF162 (B clade R5) and 6535.3 (B clade R5) showed complete
resistance to AH (IC50s .25 mg/ml) but not to 2G12, while
RHPA4259.7 (B clade R5), MW965.26 (C clade R5), and
ZM214M.PL15 (C clade R5) were susceptible to AH but resistant
to 2G12. These results indicate that the Env glycan target and/or
anti-HIV mode are different between these two proteins. Of
interest is the fact that SF162, which showed relatively high
susceptibility to AH in the hPBMC-based assay (IC50=0.48 mg/
ml, Fig. 1), was highly resistant to this protein in the TZM-bl-
based neutralization assay. On the other hand, the dual-tropic B
clade BZ167, another virus strain used in both assay formats,
showed similar sensitivity to AH (IC50s at 0.8 mg/ml in the
hPBMC-based assay vs. 2.9 mg/ml in the TZM-bl-based assay).
Figure 2. Analysis of mitogenic activity in hPBMCs. Proliferation of human CD3
+ lymphocytes in hPBMCs was analyzed by flow cytometry.
CFSE-stained hPBMCs were incubated for 5 days with 12.5 mg/ml AH, 1 mg/ml SEB (positive control; a potent T cell stimulator [21,58]), or media alone.
Samples were first gated on a viable T cell population, and the percentage of proliferating cells was determined based on the extent of CFSE dilution.
(A) Representative plots from one of three experiments are shown for CD3
+ cells. The number in each panel (above the boxed plot population)
indicates the percentage of proliferated cells. (B) Results from 3 independent experiments using different hPBMCs are shown. In addition to CD3
+
cells, CD4
+ and CD8
+ cells were analyzed to further dissect proliferative potential. Results are expressed as mean 6 SD. AH did not show any
mitogenic activity in any cell types tested.
doi:10.1371/journal.pone.0011143.g002
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with a particular Env NLG pattern, the IC50s obtained in the
TZM-bl-based neutralization assay were plotted against the
number of potential N-glycosylation sites on Env (Fig. 3). There
was no clear correlation between AH-susceptibility and the
number of sequons on whole Env or V regions. On the contrary,
a relative correlation was observed between AH susceptibility and
sequons at entire C regions (Spearman correlation coefficient
[r] =20.40, p=0.084). Site-specific analysis revealed that sequons
at the C2 segment alone have a significant correlation (r=20.51,
p=0.020). Notably, this correlation became even more apparent
when sequons at the C2 and V4 regions were combined
(r=20.65, p=0.002), even though V4 sequons alone were not
strong enough to show a significant correlation with AH-
susceptibility (p=0.176). Throughout the Envs from all the viruses
analyzed, there was no significant change in the number of
sequons in C1, C4, C5, V3, or gp41. Relatively high degrees of
numerical variations were observed in V1/V2, V5, and C3
regions, but no correlation with AH susceptibility was detected in
these regions (data not shown). Taken together, these results
suggest that NLGs at C2 and V4 may constitute the sole and/or
critical targets of AH. In Figure 4, we compared Env NLG
positions of the highly susceptible viruses (R5 B clade SS1196.1
and R5 C clade TV1.21) and resistant strains (R5 C clade
ZM109F.PB4 and R5 A clade Q259.d2.17). It was suggested that
clustering NLGs at the middle and C terminal region of C2 as well
as in V4 may play an important role in AH’s anti-HIV-1 activity.
For a comparison, we also performed the same analysis with
2G12. It was revealed that 2G12 susceptibility showed a
statistically significant correlation with the total number of sequons
located at C2, C3 and V4 (r=20.52, p=0.034) and with V4
sequons alone (r=20.53, p=0.028), but not with any other Env
regions (data not shown). These results correspond well with
previous mutagenesis and crystallographic studies that have
Figure 3. Correlation between the number of NLG sequons and AH susceptibility in Env-pseudotyped viruses. For each virus tested in
the TZM-bl-based assay, the number of NLG sites (i.e., sequons) in the indicated Env region was plotted against the IC50. The IC50 values of .25 mg/ml
were approximated to 50 mg/ml. Correlation was analyzed by the non-parametric Spearman’s correlation coefficient. The correlation coefficient (r)
and p values are shown in the box in each graph. A p value of less than 0.05 is regarded as statistically significant. Linear regression analysis was used
to display a best fit line to the data.
doi:10.1371/journal.pone.0011143.g003
Anti-HIV Lectin Actinohivin
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e11143defined the Env NLGs targeted by 2G12 [10,35], thus arguing for
the present approach to predict AH’s potential binding target(s).
Expression of rAH in N. benthamiana using a modified
TMV vector
Next, we focused on the development of an efficient rAH
expression system to facilitate the production and molecular
engineering of the protein. For this purpose, a modified TMV-
based expression system was employed [24,25]. Under our normal
plant growth conditions at 27uC, severe necrosis emerged in the
infiltrated leaves at 4 to 5 dpi. However, the necrosis was
significantly reduced by lowering the plant cultivation temperature
by 5uC, i.e., to 22uC (Fig. 5A). The expression level of rAH did not
change by this modification, according to gp120-ELISA (data not
shown). As shown in Figure 5B, the expression of rAH (Mw:
12.5 KDa) was clearly detected at 5 dpi on an SDS-PAGE gel.
Western blot analysis using polyclonal anti-AH Abs further
confirmed the expression (Fig. 5B). Interestingly, however,
apparent oligomers (dimer, trimer, etc) and aggregates were
detected along with the monomeric 12.5 kDa protein (Fig. 5B). No
oligomer formation has previously been noted for the original
actinomycete-derived AH [11,12], although an apparent dimer
was observed in E. coli-expressed rAH [36] and a minor amount of
dimers exists in a purified actinomycete-derived AH sample
(Matoba et al., unpublished observation). Therefore, the oligo-
mer/aggregate formation is unique to the TMV-based expression.
The gp120-ELISA of the leaf extract revealed that the expression
of rAH peaked at 6 dpi, with expression levels ranging from 20 to
120 mg per kg of fresh leaf material (data not shown), which
generally agrees with the intensity of the band in SDS-PAGE in
Figure 5B.
The efficient recovery of the gp120-binding fraction of rAH
from the leaf required an acidic extraction buffer containing a
chaotropic agent such as urea or guanidine HCl. After removing
the denaturant by dialysis, however, rAH remained soluble and
was largely devoid of high-order oligomers (Fig. 5B, lane 7). The
soluble plant-expressed rAH strongly bound to gp120 (Fig. 6A). To
further demonstrate plant-expressed rAH’s functional integrity, we
performed a reporter gene expression syncytium formation assay
using cells expressing human CD4 and HIV-1 Env. As seen in
Figure 6B, the X-gal staining of the cells clearly shows that plant-
expressed rAH (Fig. 6B–d), but not a reference control prepared
from a non-infiltrated leaf sample (Fig. 6B–b), inhibited the
formation of syncytia. No inhibition was observed with a sample
from GFP-expressing leaves obtained by the same TMV-based
vector (data not shown). This observation was further confirmed
by a quantitative analysis. Thus, plant-expressed rAH dose-
dependently and significantly inhibited the syncytia compared to a
control leaf sample (Fig. 6C). According to the gp120-ELISA in
Figure 4. Schematic representation of Env and potential NLG positions in selected AH-susceptible and -resistant viruses. Constant
regions (C1–C5; shown in white) and variable regions (V1–V5; shown in grey) are shown for the two most susceptible viruses (SS1196.1 and TV1.21)
and two highly resistant viruses (ZM109F.PB4 and Q259.d2.17) to AH, according to the results shown in Table 1. Black boxes indicate deletions in the
corresponding regions. Asterisks represent the position of sequons. Potential targets of AH within the C2 and V4 regions (those present in both the
susceptible viruses but absent in either of the resistant strains) are indicated by arrows.
doi:10.1371/journal.pone.0011143.g004
Figure 5. Expression of rAH in N. benthamiana. (A) Representative
TMV vector-infiltrated N. benthamiana leaves at 6 dpi. The leaves show
only a minor level of tissue necrosis. (B) Electrophoretic analysis of rAH
expression in leaf extract. Coomassie-stained SDS-PAGE gel (Lanes 1–3)
and western blot analysis (Lanes 4–7) are shown. Total leaf proteins
were extracted in a buffer containing 2% SDS and separated under
reducing conditions. Lanes 1 and 4: non-infiltrated control leaf extract;
lanes 2, 3, 5, and 6: vector-infiltrated leaf extracts made from two
independent infiltration events; and lane 7: the dialyzed aqueous
fraction of infiltrated leaf proteins prepared by 6 M guanidine buffer
extraction. Asterisks indicate the bands corresponding to rAH (Mw:
12.5 kDa). Efficient extraction of gp120-binding rAH required a buffer
containing a chaotropic agent such as SDS or guanidine HCl. The
fraction contains apparent multimers of rAH (Lanes 5 and 6). These
aggregates are largely absent after dialysis, while the monomer protein
stays soluble (Lane 7). See text for detail.
doi:10.1371/journal.pone.0011143.g005
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protein (corresponding to the far-right bar in Fig. 6C). The results
were in good agreement with the syncytium-inhibitory pattern of
the original AH sample (data not shown), indicating the integrity
of the plant-expressed protein. Taken together, these results
demonstrate that plants can serve as a new recombinant
expression platform for AH and that plant-expressed rAH is
functionally active.
Discussion
For nearly thirty years, HIV/AIDS has posed a serious global
public health concern. In the most pandemic sub-Saharan African
countries, heterosexual exposure constitutes the major route of
HIV-1 transmission, with half of the new infections occurring
among women [1]. Although condom use and male circumcision
can significantly reduce the chance of HIV-1 sexual transmission,
there is no direct countermeasure currently available at women’s
disposal [1]. Therefore, the development of a woman-controlled
microbicide is urgently needed for the control of the pandemic.
Three key factors are proposed for candidate microbicides to
move from the preclinical to clinical phase, i.e., efficacy, safety,
and economical viability [3]. We have therefore initiated our
investigation on the feasibility of AH in these aspects.
AH is an actinomycete-derived anti-HIV protein that has high
specificity to HMG clusters on Envs. Because HMGs constitute a
conserved major fraction of Env NLGs, the protein possesses high
potential as an anti-HIV agent. In the two in vitro HIV-1
neutralization assays performed here, we obtained several key
advances in understanding the anti-HIV-1 activity profile of AH.
First, AH’s anti-HIV-1 effect was demonstrated in a hPBMC-
based assay using primary isolates and in a TZM-bl-based assay
using Env-pseudotyped viruses of clinically-relevant strains from
major clades. These two in vitro assay formats are currently
recommended for evaluating the anti-HIV-1 activity of neutral-
izing Abs, hence entry/fusion inhibitors, to best predict their in vivo
antiviral efficacies [37]. In both assay systems AH exhibited clear
anti-HIV-1 effects against many clinically relevant viruses,
including those of the mucosally transmitted R5-type. In addition,
the activity dose ranges of AH were similar between the two
systems overall, which are also consistent with previous results in
another cell-line based surrogate neutralization assay system (IC50s
at the nanomolar range; [15]). Taken together, it is strongly
argued that AH is a broadly neutralizing anti-HIV-1 lectin that
could potentially blunt mucosal HIV-1 transmission of primary R5
viruses. Further studies are required to predict the protein’s
activity upon microbicide use. For example, it is critical to test the
anti-HIV-1 effect in in vitro studies more closely simulating the
physiological conditions in the vagina, e.g., in the presence of
seminal plasma and under a pH transition that takes place during
the coital event [38]. Sustained efficacy under these conditions,
along with safety (as discussed below), are prerequisites for any
microbicide candidate.
While AH’s anti-HIV-1 effects in the hPBMC-based- and
TZM-bl-based neutralization assays fell into a similar range, there
was a significant difference in the sensitivity of the B clade SF162
Figure 6. Activity analysis of N. benthamiana-expressed rAH. (A)
The gp120-binding capacity of rAH expressed in N. benthamiana was
evaluated by gp120-ELISA using AH-expressing and control (uninfil-
trated) leaf extracts prepared as described in Materials and Methods.
Results of a representative sample obtained from a ,2 g batch of leaf
materials are shown. Data points are the means 6 SD of triplicate
analysis. This analysis was also used to determine the quantity of rAH in
the extract based on a standard curve created by actinomycete-derived
purified AH. (B) X-gal staining of syncytia formation by HeLa/Env/tat
and HeLa/CD4/LacZ. The two cell lines were incubated for 18 h at 37uC
with: a, media alone; b, 1/20-diluted non-infiltrated control leaf sample;
c,1mM actinomycete-derived AH; and d, 1/20-diluted rAH-expressing
leaf sample (containing approximately 0.32 mM, or 4.0 mg/ml, of rAH, as
determined by gp120-ELISA). (C) Quantitative analysis of syncytia
formation by HeLa/Env/tat and HeLa/CD4/LacZ. The two cell lines were
incubated for 18 h at 37uC with serially diluted control or rAH-
expressing leaf samples. See Materials and Methods for the assay detail.
Differences between the samples at each dilution point were evaluated
by two-way analysis of variance followed by Bonferroni posttests
(*** p,0.001).
doi:10.1371/journal.pone.0011143.g006
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and .25 mg/ml in the latter; see Fig. 1 and Table 1). Multiple
studies have reported similar discrepancies in inhibitory patterns of
neutralizing Abs between the two assay systems [16,37]. In our
case, the conflicting result may be a reflection of the phenotypic
difference in viruses produced in these assays, i.e., the primary
isolate produced in hPBMCs versus the Env-pseudotyped virus
produced in 293T cells. It has been shown that the N-glycan
structure of viral glycoproteins can vary depending on the cell type
in which the virus is produced [14,39,40]. For example, HIV-1
gp120 s produced in human PBMCs were shown to have more
HMGs than those produced in monocyte-derived macrophages
[14]. Because AH targets Env HMGs, it is conceivable that viruses
harboring more HMGs on their Envs would be more susceptible
to the protein. Thus, although there is no direct information as to
the glycan profiles of SF162 Envs produced in hPBMCs and 293T
cells, the higher AH sensitivity of the hPBMC-produced virus may
be explained by the higher number of HMGs on the Env.
Alternatively, a potential difference in the Env density on the
viruses used in the two different systems may account for the
discrepancy in viral AH sensitivity, as has been reported [41,42].
In any event, the above may imply that a future efficacy study of
AH or other relevant anti-HIV-1 agents should include testing of
viruses present in semen [43,44].
Second, we uncovered the breadth of AH’s anti-HIV-1 effect in
the TZM-bl-based neutralization assay. It was revealed that AH
possesses anti-HIV-1 activity against many clinically relevant R5
viruses, having the neutralization breadth similar to that of the
HMG-targeting broadly neutralizing mAb 2G12. This is not
surprising because both 2G12 and AH recognize the Mana1–
2Man moiety of HMGs [9,10,12,35]. However, a few discrepan-
cies in the neutralization patterns between 2G12 and AH indicate
that their target HMGs are not identical (discussed later). AH may
generally be more effective against R5 C clade viruses than 2G12,
as the former neutralized four viruses while the latter inhibited
only two out of the five viruses tested at lower than 25 mg/ml
(Table 1). This points to an advantage of AH because the C clade
is highly prevalent in epidemic regions where over 80% of total
global HIV-1 infections occur [33,34], although analysis must be
expanded to validate this concept. On the other hand, both AH
and 2G12 showed lack of efficacy to all the four A clade viruses.
Interestingly, relative resistance of A clade viruses has previously
been observed for another potent mannose-specific anti-HIV-1
lectin, GRFT [45]. These results may indicate the general
resistance of A clade viruses to HMG-targeting HIV-1 inhibitors
and imply a potential weakness for this class of anti-HIV agent.
Alternatively, this warrants investigation of more in depth clade-
specific analysis and identification of a different type of anti-HIV
agent that can supplement AH or other HMG-targeting HIV-1
inhibitors toward an effective combination microbicide strategy.
Third, correlation analysis between AH susceptibility and Env
NLG profiles suggested that several NLGs might be targeted by
AH. These glycans tend to cluster at the middle and at the C-
terminal region of C2 and at V4 (Fig. 4). A recent crystallographic
analysis indicated that AH possesses three carbohydrate-binding
sites and that each of these appeared to accommodate a couple of
Mana1–2Man moieties from the D1 and D3 arm of a single HMG
[12]. Our results suggest that NLGs at the C2 and V4 regions may
comprise a set of HMGs recognized by AH’s three sugar binding
sites. This notion is supported in part by the previous studies
showing that NLGs at these locations tend to contain more HMGs
than other regions [46,47,48]. Obviously, further studies are
needed to demonstrate AH’s target Env NLGs, e.g., crystallogra-
phy of an AH-gp120 complex, and analysis of escape and mutant
viruses displaying modified Env NLG patterns. Such studies will
also help dissect the molecule’s anti-HIV-1 mechanism to aid the
development of potent AH analogues and are ongoing in our
laboratories.
AH is similar to CV-N in that both lectins recognize the
Mana1–2Man structure of HMGs and thereby exert anti-HIV-1
activity, although the former relies on high-avidity interaction with
multiple HMGs while the latter is specific to a single HMG
[12,49,50]. CV-N is a leading lectin-based microbicide candidate
that has shown promising results in macaque challenge studies
[51,52] and in a human cervical explant infection model [53].
However, recent studies have shown that CV-N possesses
cytotoxicity and mitogenic activity with pro-inflammatory re-
sponses in hPBMCs at nanomolar concentrations, which are very
close to the protein’s antiviral dose range [29,30]. These
deleterious and pro-infective actions have raised a serious concern
for CV-N’s candidacy toward microbicide use. Indeed, such
activities are common features of lectins (with a few notable
exceptions, e.g., GRFT [45]), necessitating careful examination of
lectin-based HIV-1 inhibitors in these aspects. In spite of the
similarity between CV-N and AH in sugar binding specificity, our
results demonstrated that AH is devoid of cytotoxicity or
mitogenic activity in hPBMCs at concentrations where the protein
exerts potent anti-HIV-1 effects. We recognize that more
thorough analyses, including inflammatory and immunogenicity
endpoints, must be performed for higher doses of AH to conclude
the protein’s safety. Nevertheless, when combined with AH’s
exquisite specificity to Env glycans and preliminary results showing
the lack of toxicity in a rabbit vaginal irritation assay with 0.1%
AH solution (Tanaka et al. manuscript in preparation), our results
provide a reasonable foundation supporting the protein’s safety
and should facilitate further investigation in this regard.
Microbicides will be required in massive amounts at low costs,
considering the application frequency and estimated target
population of those millions living in developing regions where
HIV-1 infections are most prevalent. Accordingly, a key factor for
the success of protein-based HIV-1 microbicides is the establish-
ment of a scalable and cost-effective recombinant expression
system; however conventional closed cell culture-based systems
may not be able to meet these requirements [54]. Plants have
recently emerged as an alternative recombinant expression system
that has the potential to mass produce foreign proteins at
substantially low costs [55,56,57]. In particular, the advent of
recombinant plant virus vector systems enabled rapid and high-
level expression of foreign proteins in plants. In the present study,
we showed that rAH expressed via a TMV-based system can bind
to gp120 and inhibit syncytia mediated by the Env-CD4
interaction, which demonstrates the protein’s functional integrity.
Although there is room for improvement (e.g., reducing rAH’s
aggregate formation in planta), we obtained a comparatively high
expression level (up to 120 mg of functional rAH per kg of fresh leaf
material) for plant-based expression systems in general [55]. In
addition, the functional portion of rAH was readily separated and
recovered from the aggregates after extraction (Fig. 5B). Conse-
quently, we have successfully developed a novel rAH expression
platform in plants. A logical and essential next step, which is
currently underway, is the detailed characterizations of rAH in
terms of molecular integrity, anti-HIV-1 efficacy, and safety using
thoroughly purified material.
Compared to other lectins that have been reported to exhibit
anti-HIV-1 effects (reviewed in [7]), AH’s antiviral activity
reported here is not the strongest in this class. Notwithstanding
the moderate anti-HIV-1 efficacy, AH’s apparent lack of
mitogenicity and cytotoxicity in hPBMCs demonstrated here is a
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lectins. Using rDNA technology, it may be possible to engineer
rAH derivatives that have stronger anti-HIV activity while
maintaining quiescence in the toxicological aspects. In fact, in
our preliminary study, a recombinantly engineered AH dimer
construct (native AH is a monomeric protein [12]) was shown to
exhibit significantly stronger and broader anti-HIV-1 activity than
the original monomer molecule. For example, two clade A viruses
that showed strong resistance to AH (Q461.e2 and Q168.a2; see
Table 1) were strongly neutralized by the dimer with IC50s less
than 1 mg/ml (Tanaka & Matoba, manuscript in preparation).
Based on the speed and robustness, the TMV-based rAH
expression system will further facilitate the design of additional
rAH analogues that have even more potent anti-HIV-1 activity
and other desirable properties for microbicide use (e.g., produci-
bility, bioavailability, formulability, etc.). Taken together, the
TMV-based system may provide a viable means for the
economical large-scale production as well as the design of rAH
derivatives, which both significantly facilitate the development of
rAH-based microbicide candidates.
In summary, we have demonstrated that: 1) AH exerts
nanomolar-level antiviral activity against many clinically relevant
HIV-1 strains of different clades and diverse cellular tropisms (with
a possible exception for R5-type A clade viruses); 2) AH does not
possess cytotoxicity or mitogenic activity in hPBMCs at doses
showing broad anti-HIV-1 activity; and 3) the TMV-based system
serves as a novel rAH expression platform that may facilitate
molecular engineering and economical large-scale production.
Based on these initial efficacy, safety, and producibility data, we
propose that AH is promising as a precursor of new candidate
HIV-1 microbicides targeting Env glycans. Further investigation
on efficacy and safety, analysis of mechanisms of action, and
design of potent analogues are warranted. Future studies should
also investigate potential antiviral synergism between rAH
derivatives and other antivirals toward an effective combination
microbicide strategy.
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